Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
NACompletedINTERVENTIONAL
Enrollment
1
Participants
Timeline
Start Date
March 23, 2016
Primary Completion Date
August 30, 2019
Study Completion Date
November 5, 2019
Conditions
Refractory Solid Tumors
Interventions
DRUG
sunitinib
Trial Locations (1)
135-710
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT02450123 - Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors | Biotech Hunter | Biotech Hunter